Skip to content

Your Partner in SCA Risk Management

ASSURE-Protect-Graphic_compressed

 

GDMT Takes Time. SCD Doesn’t Wait.

The first 90 days after diagnosis carry the highest risk of sudden cardiac death (SCD) in patients with reduced EF (≤35%)leaving a critical gap in protection as GDMT is titrated to full effect.1
HFSA-LP-Card_higher_risk
IMG-026C-Graphic,-SCD-PROTECT-Time-to-Appropriate-Treatment,-Graph

Protecting Against SCD Is Only Half the Story

Anchored by the ASSURE® WCD, the Cardiac Recovery System® (CRS) platform bridges the gap by pairing proven protection with insights to support recovery. 

The Cardiac Recovery System platform:

  • Provides insights that may be helpful in care optimization, including arrhythmia detection (VT/VF, SVT and bradyarrhythmia) and physiologic trends (heart rate and activity)
  • Extends care team's reach through timely clinical alerts & rapid post-shock support

By combining proven therapy with increased visibility, the CRS platform empowers providers to protect patients and support their recovery as GDMT reaches full effect.  

hfsa-circle_products_opaque-1
Raise the standard for sudden cardiac arrest (SCA) risk management
  1. Duncker D. et al. Eur Heart J. 2025;00:1–10.
  2. Duncker D, et al. Clin Cardiol. 2017;40(8):586-590.   

 

The Cardiac Recovery System Platform Empowers Confident Care

Designed for Daily Life

hfsa-circle-garment-female

With the most customizable fit in the category—seven sizes and two styles—the ASSURE system delivers exceptional comfort and compliance.

  • Worn for more than 23 hours per day3
  • Up to 87% fewer patients experiencing false alarms than competing WCD patients*3,4

 

 


*Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.

Insights to Inform Care

hfsa-circle_insights

In real-world use, the ASSURE system identified potentially actionable cardiac events5,6:

  • Detected arrhythmias in 18% of patients, leading to physician-directed clinical intervention
    • VT/VF in 7% of patients, including asymptomatic events
    • SVTs in 11% of patients, including AF/AFL
  • Helped identify previously undiagnosed atrial fibrillation in 5.5% of patients with high stroke risk
  • Recorded asymptomatic VT in 3.6% of patients, supporting further clinical review for ICD eligibility

An Extension of Your Care Team

hfsa-circle_physician

Connected services enable timely clinical intervention and patient support.

  • Heart Alert Services identifies and notifies providers of cardiac events that may warrant action, supporting optimization of care.
  • Following a shock, the ASSURE® Assist service is designed to connect patients to the urgent support they need.
  1. ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS) NCT05135403, Cohort April 2024.
  2. Arkles, J. et al. J Interv Card Electrophyiol. 2023;66(7):1723-1728.
  3. Phukan A. et el. Clinical Impact of Ventricular and Supraventricular Arrhythmia Detection with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024. Chicago, IL.
  4. Syed Z, et el. Initial Real-world Experience with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024. Chicago, IL.

 

Connect With Us

Stay Up to Date

Follow us on social:

social-linkedin   social-x   social-facebook

MKT-00162-01_B